Floatz logo

19 assets in Urethra Transitional Cell Carcinoma

Therapeutic assets addressing Urethra Transitional Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
Urethra Transitional Cell Carcinoma
Nagoya UniversityP3BB (70)
Nivolumab
Urethra Transitional Cell Carcinoma
Nagoya UniversityP3BB (70)
Cyclophosphamide
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BB (67)
Pembrolizumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BB (67)
Atezolizumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3BB (64)
Relatlimab
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P2/3BB (64)
Durvalumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (60)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P2B (60)
Ipilimumab
Urethra Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2B (59)
Avelumab
Urethra Transitional Cell Carcinoma
Alliance for Clinical Trials in OncologyP3B (57)
Apsolol
Urethra Transitional Cell Carcinoma
Emory UniversityP2CCC (53)
Eribulin Monomethanesulfonate
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P2CCC (53)
Tamivarotene
Urethra Transitional Cell Carcinoma
Nagoya UniversityP2CCC (53)
Tocilizumab
Urethra Transitional Cell Carcinoma
M.D. Anderson Cancer CenterP2CCC (53)
Carboplatin
Urethra Transitional Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Docetaxel
Urethra Transitional Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Etoposide
Urethra Transitional Cell Carcinoma
Jonsson Comprehensive Cancer CenterP1CC (43)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P1CC (43)
Cabozantinib
Urethra Transitional Cell Carcinoma
National Cancer Institute (NCI)P1NR ()